Accumulation of regulatory T cells in sentinel lymph nodes is a prognostic predictor in patients with node-negative breast cancer

European Journal of Cancer

Volumn 45, Issue 12, 2009, Pages 2123-2131

  Nakamura, Rikiya ^a   Sakakibara, Masahiro ^a   Nagashima, Takeshi ^a   Sangai, Takafumi ^a   Arai, Manabu ^a   Fujimori, Toshihiko ^a   Takano, Shigetsugu ^a   Shida, Takashi ^a   Nakatani, Yukio ^a   Miyazaki, Masaru ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Foxp3; Immune marker; Micrometastasis; Prognostic predictor; Regulatory T cells; Sentinel lymph nodes

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; TAMOXIFEN CITRATE; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MICROMETASTASIS; MULTIVARIATE ANALYSIS; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE BIOPSY; T-LYMPHOCYTES, REGULATORY; TUMOR MARKERS, BIOLOGICAL;

EID: 67650935136     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.03.024     Document Type: Article

References (31)

1. Carter C.L., Allen C., and Henson D.E. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63 (1989) 181-187
2. Page D.L., Jensen R.A., and Simpson J.F. Routinely available indicators of prognosis in breast cancer. Breast Cancer Res Treat 51 (1998) 195-208
3. Jatoi I., Hilsenbeck S.G., Clark G.M., and Osborne C.K. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol 17 (1999) 2334-2340
4. Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thurlimann B., and Senn H.J. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21 (2003) 3357-3365
5. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
6. Krag D., Weaver D., Ashikaga T., et al. The sentinel node in breast cancer - a multicenter validation study. New Engl J Med 339 (1998) 941-946
7. Badwe R.A., Thorat M.A., and Parmar V.V. Sentinel-node biopsy in breast cancer. New Engl J Med 349 (2003) 1968-1971
8. Bostick P.J., Huynh K.T., Sarantou T., et al. Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple-marker RT-PCR. Int J Cancer 79 (1998) 645-651
9. Groen R.S., Oosterhuis A.W., and Boers J.E. Pathologic examination of sentinel lymph nodes in breast cancer by a single haematoxylin-eosin slide versus serial sectioning and immunocytokeratin staining: clinical implications. Breast Cancer Res Treat 105 (2007) 1-5
10. Weigelt B., Verduijn P., Bosma A.J., Rutgers E.J., Peterse H.L., and van't Veer L.J. Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers. Brit J Cancer 90 (2004) 1531-1537
11. Dell'Orto P., Biasi M.O., Del Curto B., Zurrida S., Galimberti V., and Viale G. Assessing the status of axillary sentinel lymph nodes of breast carcinoma patients by a real-time quantitative RT-PCR assay for mammaglobin 1 mRNA. Breast Cancer Res Treat 98 (2006) 185-190
12. Kohrt H.E., Nouri N., Nowels K., Johnson D., Holmes S., and Lee P.P. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2 (2005) e284
13. Vuylsteke R.J., van Leeuwen P.A., Meijer S., et al. Sampling tumor-draining lymph nodes for phenotypic and functional analysis of dendritic cells and T cells. Am J Pathol 161 (2002) 19-26
14. Poindexter N.J., Sahin A., Hunt K.K., and Grimm E.A. Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Res 6 (2004) R408-R415
15. Kim R., Emi M., Tanabe K., and Arihiro K. Immunobiology of the sentinel lymph node and its potential role for antitumour immunity. Lancet Oncol 7 (2006) 1006-1016
16. Matsuura K., Yamaguchi Y., Ueno H., Osaki A., Arihiro K., and Toge T. Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer 106 (2006) 1227-1236
17. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22 (2004) 531-562
18. Liyanage U.K., Moore T.T., Joo H.G., et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169 (2002) 2756-2761
19. Ichihara F., Kono K., Takahashi A., Kawaida H., Sugai H., and Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9 (2003) 4404-4408
20. Ormandy L.A., Hillemann T., Wedemeyer H., Manns M.P., Greten T.F., and Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65 (2005) 2457-2464
21. Schaefer C., Kim G.G., Albers A., Hoermann K., Myers E.N., and Whiteside T.L. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Brit J Cancer 92 (2005) 913-920
22. Hori S., Nomura T., and Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 (2003) 1057-1061
23. Curiel T.J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004) 942-949
24. Viguier M., Lemaitre F., Verola O., et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173 (2004) 1444-1453
25. Hiraoka N., Onozato K., Kosuge T., and Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12 (2006) 5423-5434
26. Miller A.M., Lundberg K., Ozenci V., et al. CD4+CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 177 (2006) 7398-7405
27. Bates G.J., Fox S.B., Han C., et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24 (2006) 5373-5380
28. Nagashima T., Sakakibara M., Nakano S., et al. Sentinel node micrometastasis and distant failure in breast cancer patients. Breast Cancer 13 (2006) 186-191
29. Chu P.G., and Weiss L.M. Keratin expression in human tissues and neoplasms. Histopathology 40 (2002) 403-439
30. Visser M., Jiwa M., Horstman A., et al. Intra-operative rapid diagnostic method based on CK19 mRNA expression for the detection of lymph node metastases in breast cancer. Int J Cancer 122 (2008) 2562-2567
31. Moore K.H., Thaler H.T., Tan L.K., Borgen P.I., and Cody III H.S. Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma: biologic metastasis or procedural artifact?. Cancer 100 (2004) 929-934